Methylphenidate
Prescription stimulant for ADHD; tightly controlled because it can be misused and cause dependence.

Related comparisons
Modafinil vs MethylphenidateDETAILED OVERVIEW
What is Methylphenidate?
Methylphenidate (Ritalin, Concerta) is a prescription stimulant medicine and the usual first-choice treatment for attention deficit hyperactivity disorder (ADHD); it is also used in narcolepsy. Because of the risk of misuse it is tightly controlled: in Hungary it can only be prescribed on a narcotics prescription, and in the United States it is in the controlled category for drugs with a high risk of abuse.
It blocks the reuptake of the brain messengers dopamine and noradrenaline, which improves attention, impulse control and working memory. It can reduce appetite (about 30% of users) and temporarily slow growth in children. It raises heart rate and blood pressure and in serious heart disease can cause sudden cardiac death, stroke or heart attack. It can also cause anxiety and, rarely, hallucinations and aggression. Used in ways other than prescribed it can cause amphetamine-like euphoria, and with long-term use dependence and withdrawal can develop.
ATC code
N06BA04
Prescription
Prescription only (Rx), narcotic Rx; DEA Schedule II
Mechanism
DAT/NET reuptake inhibitor CNS stimulant (dopamine + norepinephrine)
Half-life
About 3.5 hours (immediate-release form); extended-release effect lasts 10–12 hours
Onset
Immediate-release 30–45 min, peak effect 1–3 hours; extended-release 1–2 hours
Anecdotal reports describe Methylphenidate as a clean, well-titrated DAT/NET inhibitor for ADHD, with strong dopaminergic wakefulness comparable to first-line stimulants. Community accounts note a smoother, more focused subjective profile than many off-label alternatives, without aggressive mental pressure. Users with poor tolerance to peripheral stimulant effects often report better day-long stability on extended-release formulations (Concerta, Ritalin LA). Rx context emphasizes Schedule II status, abuse potential, and the need for clinician-monitored titration. Sleep architecture impact appears milder than amphetamine-class stimulants, though late-day dosing can still disrupt sleep onset.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
MTA Cooperative Group. . A 14-month randomized clinical trial of treatment strategies for ADHD (MTA Cooperative Group). Arch Gen Psychiatry. 1999;56(12):1073-86..
Storebø OJ, Pedersen N, Ramstad E et al. . Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2018;5:CD012069..
Hinshaw SP, Arnold LE, MTA Cooperative Group . Attention-deficit hyperactivity disorder, multimodal treatment, and longitudinal outcome: evidence, paradox, and challenge.. Wiley Interdiscip Rev Cogn Sci.
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Cardiovascular effects: increased heart rate, modest blood pressure rise, palpitations. Boxed-warning-level concern: risk of sudden death, stroke and myocardial infarction in people with structural cardiac abnormalities or serious heart disease, especially with misuse.
- Dependence and abuse (Schedule II): chronic use carries risk of tolerance, psychological dependence and withdrawal; crushed-insufflated or injected use produces amphetamine-like euphoria and high abuse potential.
- Psychiatric effects: anxiety, irritability, mood lability; rarely new treatment-emergent psychotic or manic symptoms (hallucinations, paranoia) even without prior history, plus aggression and hostility.
- Decreased appetite (~30%) and weight loss; in children a transient slowing of growth (height and weight), so regular growth monitoring is required.
- Insomnia and sleep disturbance, especially with late-afternoon or evening dosing (avoid after 4 PM); headache, dizziness, dry mouth.
- Peripheral vascular effects: Raynaud phenomenon and peripheral vasospasm, rarely digital ischemia with chronic use; discoloration of fingers should be reported.
- Priapism: rare but urological emergency involving prolonged, painful erection, requiring immediate care to prevent lasting tissue damage.
- Onset or worsening of motor and vocal tics; rarely serotonin syndrome when combined with serotonergic drugs (e.g. MAO inhibitors).
Contraindications · 4
- MAOi within 14 days (hypertensive crisis)
- Severe CV disease (LV hypertrophy, severe hypertension, coronary insufficiency)
- Hyperthyroidism, angle-closure glaucoma
- Active substance dependence, psychotic symptom history (relative)
Related Pharmaceuticals
Same therapeutic category
Studies
Related research and clinical findings
A 14-month randomized clinical trial of treatment strategies for ADHD (MTA Cooperative Group)
MTA Cooperative Group.
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Storebø OJ, Pedersen N, Ramstad E et al.
Attention-deficit hyperactivity disorder, multimodal treatment, and longitudinal outcome: evidence, paradox, and challenge.
Hinshaw SP, Arnold LE, MTA Cooperative Group
Telegram
Have a question about Methylphenidate?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.